Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

Inclusion Criteria:

• Signed informed consent must be obtained prior to participation in the study.

• Male and female participants ≥ 18 years of age, at the time of ICF signatures andwith a diagnosis of PNH confirmed by treating physician.

• Stable regimen (dose and intervals) of anti-C5 antibody treatment (either eculizumabor ravulizumab) for at least 6 months prior to screening

• Mean hemoglobin level ≥10 g/dL

• Vaccination against Neisseria meningitidis and S. pneumoniae infection are requiredprior to the start of iptacopan treatment.

• If not received previously, vaccination against Haemophilus influenzae infections isrecommended, if available and according to local regulations.

• Ability to communicate well with the investigator, to understand and comply with therequirements of the study

• Other protocol -defined inclusion criteria may apply at the end.

Exclusion Criteria:

• Participation in any other investigational drug trial or use of otherinvestigational drugs at the time of enrollment

• Patients requiring red blood cell transfusion in the 6 months prior to screening orduring screening

• History of stem cell transplantation or any solid organ transplantation

• Active systemic bacterial, viral (incl. COVID-19) or fungal infection within 14 daysprior to study drug administration

• Presence of fever ≥ 38.0 °C (100.4 °F) within 7 days prior to study drugadministration

• Human immunodeficiency virus (HIV) infection (known history of HIV or test positivefor HIV antibody at Screening)

• A history of recurrent invasive infections caused by encapsulated organisms, e.g.meningococcus or pneumococcus

• Unstable medical condition including, but not limited to, myocardial ischemia,active gastrointestinal bleeding, coexisting chronic anemia unrelated to PNH, orunstable thrombotic event not amenable to active treatment as judged by theinvestigator at Screening.

• History of cancer of any part of the body within the past 5 years,

• Ongoing drug or alcohol abuse that could interfere with patient's participation inthe trial.

• Any medical condition deemed likely to interfere with the patient's participation inthe study

• Female patients who are pregnant or breastfeeding, or intending to conceive duringthe course of the study